Evogene Ltd. Form 6-K Report: Upcoming Shareholder Meeting Insights

Key Information Extracted from the Financial Report (Form 6-K)

1. Company Overview:

• Name: Evogene Ltd.
• Address: 13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel.

2. Filing Details:

• Type: Form 6-K (Report of Foreign Private Issuer)
• Commission File Number: 001-36187
• Date of Report: December 30, 2024

3. Special General Meeting of Shareholders:

• Date and Time: Scheduled for February 5, 2025, at 3:00 PM (Israel time).
• Eligibility to Vote: Shareholders of record as of January 6, 2025, are entitled to vote at the meeting.

4. Meeting Documentation:

• Notice of Meeting: Attached as Exhibit 99.1, includes agenda, required majority for proposal approvals, and voting procedures.
• Proxy Statement: Attached as Exhibit 99.2, provides detailed information on the proposals, background information, logistical voting details, and information about the board of directors.
• Proxy Card: Attached as Exhibit 99.3, serves as the primary means for shareholders to cast votes on the proposals.

5. Additional Information:

• The contents of Exhibits 99.1, 99.2, and 99.3 are incorporated by reference in related registration statements (Form F-3 and Form S-8).

6. Signatory:

• Signed by: Yaron Eldad, Chief Financial Officer of Evogene Ltd.

Insights:

• Evogene Ltd. is actively engaging its shareholders through a special general meeting, which indicates ongoing corporate governance and shareholder interaction practices.
• The meeting scheduled for February 2025 suggests that the company may be discussing significant proposals that could impact its strategic direction or corporate structure.
• The requirements for voting participation highlight the importance of shareholder involvement in corporate decisions, a key aspect of maintaining transparency and accountability in public companies.